debt_leverage_profile
Pre-revenue clinical-stage company; minimal debt, relies on equity financing; ~$0 long-term debt as of latest filings
Inferred
Agent_Inference
interest_rate_sensitivity
Negligible direct debt interest exposure; higher rates increase cost of future equity/debt raises, pressuring cash runway
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Single-source biologics (human vein allografts) from US tissue banks; any EU regulatory restriction on allograft import is second chokepoint
Inferred
Agent_Inference
international_expansion_readiness
No meaningful international revenue yet; clinical trials EU-based create euro exposure but no significant currency devaluation risk currently
Inferred
Agent_Inference
geographic_footprint
Primarily US-domiciled; EU clinical trial sites (Netherlands/Germany); negligible foreign revenue exposure to sovereign currency devaluation
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Human vein allograft supply from limited US tissue bank network likely represents non-substitutable critical input; high single-supplier dependency risk
Inferred
Agent_Inference
business_model_type_primary
Medical device/biologics; not cloud-dependent for core product delivery; AWS/GCP termination would disrupt back-office, not product viability
Inferred
Agent_Inference
business_model_type_secondary
Clinical-stage biotech/device hybrid; secondary model involves regulatory-driven milestone payments and potential licensing/partnership revenue
Inferred
Agent_Inference
switching_cost_profile
No significant API coupling; core product is a biologic vascular device; software/cloud API dependency is minimal and substitutable
Inferred
Agent_Inference
howey_test_risk_index
Low Howey Test risk; revenue model is medical device sales to clinicians; no investment contract or token-like instrument in primary revenue stream
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Limited patient data handling; GDPR exposure from EU trial sites is moderate; CCPA exposure low given no consumer data monetization
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; niche vascular access device market with multiple competitors; no dominant market share or exclusionary conduct evident
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Currently pre-revenue; future revenue expected to be transactional (per-device sales) with potential GPO/hospital contracts; ~0% recurring currently
Inferred
Agent_Inference
monetization_vector
Per-unit device sales to hospitals and dialysis centers; potential recurring consumable pull-through from implanted devices over patient lifetime
Inferred
Agent_Inference
pricing_architecture
Premium pricing strategy targeting $5,000–$15,000 per device implant; reimbursement-dependent; stress point is CMS/payer coverage determination
Inferred
Agent_Inference
pricing_power_rating
Moderate; if clinical outcomes superior to AV fistula/graft, pricing power exists; but hospital procurement and payer reimbursement cap upside
Inferred
Agent_Inference
target_gross_margin_bracket
597.1% Gross Margin (Premium (>60%))
High
SEC-XBRL
churn_vulnerability_index
No free-rider leakage applicable; one-time implant device with no subscription; patient retention irrelevant post-implant; surgeon re-adoption is key risk
Inferred
Agent_Inference
headcount_cost_structure
Growth is sublinear post-commercialization; manufacturing scale and sales force expansion needed but not 1:1 with revenue; device economics favor leverage
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of incremental device is dominated by allograft procurement and processing; SG&A scales slower than revenue at commercial scale
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; no franchise network; direct hospital/clinic sales model with standard medical device regulatory compliance requirements
Inferred
Agent_Inference
customer_acquisition_metric
CAC at 10x scale expected to decline as clinical evidence builds; key driver is KOL adoption and GPO contracts; estimated CAC heavy upfront
Inferred
Agent_Inference
network_effect_present
No network effects; device utility is independent per patient; adoption driven by clinical outcomes data and physician training, not user base size
Inferred
Agent_Inference
asset_efficiency_ratio
-65.9% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate resilience; dialysis access is medically necessary but elective procedure timing may shift; renal failure patient base is inelastic demand
Inferred
Agent_Inference
customer_segment_primary
Nephrologists and interventional radiologists at dialysis centers and hospitals treating end-stage renal disease (ESRD) patients requiring vascular access
Inferred
Agent_Inference
customer_segment_secondary
Large dialysis networks (DaVita, Fresenius) represent potential concentrated buyer risk; top 2 chains control ~70% of US dialysis market
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
16.0% CapEx / Revenue (High-CapEx Infrastructure)
High
SEC-XBRL
sec_cik
0001661053
High
SEC-EDGAR
ticker
NVNO
High
SEC-EDGAR